High-mobility group box-1 peptide ameliorates bronchopulmonary dysplasia by suppressing inflammation and fibrosis in a mouse model

• Published in: Biochemical and biophysical research communications 2023-09, Vol.671, p.357-365
• Main Authors: Hara, Takeya, Shimbo, Takashi, Masuda, Tatsuo, Kitayama, Tomomi, Fujii, Makoto, Hanawa, Morifumi, Yokota, Kazuha, Endo, Masayuki, Tomimatsu, Takuji, Kimura, Tadashi, Tamai, Katsuto
• Format: Article
• Language: English
• Subjects: Animals; Animals, Newborn; Bronchopulmonary dysplasia; Bronchopulmonary Dysplasia - drug therapy; Bronchopulmonary Dysplasia - genetics; Chronic lung disorder; Cytokines - adverse effects; Disease Models, Animal; Fibrosis; HMGB1; HMGB1 Protein - metabolism; Humans; Hyperoxia - pathology; Infant, Newborn; Inflammation - drug therapy; Inflammation - pathology; Lung - pathology; Lung Injury - pathology; Mesenchymal stem cell; Mice; Peptide; Single-cell RNA sequencing
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2023.06.032

This study aimed to examine the effect of the HMGB1 peptide on Bronchopulmonary dysplasia (BPD)-related lung injury in a mouse model. HMGB1 peptide ameliorates lung injury by suppressing the release of inflammatory cytokines and decreasing soluble collagen levels in the lungs. Single-cell RNA sequencing showed that the peptide suppressed the hyperoxia-induced inflammatory signature in macrophages and the fibrotic signature in fibroblasts. These changes in the transcriptome were confirmed using protein assays. Systemic administration of HMGB1 peptide exerts anti-inflammatory and anti-fibrotic effects in a mouse model of BPD. This study provides a foundation for the development of new and effective therapies for BPD. •Bronchopulmonary dysplasia (BPD) is a chronic lung disorder.•HMGB1 peptide exerts anti-inflammatory and anti-fibrotic effects.•HMGB1 peptide may be used clinically in the treatment of BPD in the future.